## Human Reviewer 1

### Questions
None

### Rating
2

### Confidence
4

---

## Human Reviewer 2

### Questions
Please refer to "Strengths And Weaknesses"

### Rating
2

### Confidence
5

---

## Human Reviewer 3

### Questions
1. Section 3.3 proposes multiple filtering processes, but how these filters interact with the LLM agents remains unclear. The agents seem primarily described as data crawlers rather than intelligent decision-makers. Can the authors explicitly clarify the value added by incorporating LLM agents, and justify their presence in the paper title? Is their functionality sufficiently critical compared to standard data collection methods?
2. Section 4.5 outlines metrics like spatiotemporal similarity and outbreak expansion rates. However, this discussion remains superficial. Could the authors elaborate more comprehensively on how the metrics are specifically chosen, quantified, and how can these metrics be integrated into the RL-based training and evaluation pipeline? Additionally, how would these metrics handle conflicting signals or noise from disparate sources?
3. The middle-layer design claims to output validated signals using RL optimization, yet the pilot study only experiment on sentiment classification. Given that epidemic signals are complex, can the authors clarify how stability and convergence in this RL-based system would be achieved, especially given multiple potentially conflicting optimization objectives? Has this approach been tested or simulated beyond sentiment analysis tasks?
4. The paper emphasizes human-in-the-loop validation, but practical workflows remain underspecified. Could the authors provide concrete examples or scenarios illustrating the integration between human expertise and automated LLM outputs? Specifically, how would workflows be structured, responsibilities delineated, and final decision-making authority managed?
5. How do the authors plan to address significant regulatory challenges inherent to such a globally distributed system, especially concerning data privacy laws, compliance across diverse jurisdictions, and varying levels of technological resources among public health institutions?

### Rating
2

### Confidence
4

---

## Human Reviewer 4

### Questions
1. Can you provide more details on how the integration of federated learning and secure multi-party computation will address privacy and regulatory challenges across different regions?
2. Given the complexity and reliance on LLMs and reinforcement learning, what specific measures are in place to manage and mitigate the risk of false positives or misclassifications in high-stakes public health scenarios?

Minor suggestions:
1. ··expert modules” in line 200 with wrong double quotation marks
2. Replicated subsection 4.3.

### Rating
3

### Confidence
4